Bionano Genomics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
BNGO$1.16+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue: | ||
| Product revenue | $26,727,000 | $20,425,000 |
| Service and other revenue | 9,389,000 | 7,377,000 |
| Total revenue | 36,116,000 | 27,802,000 |
| Cost of revenue: | ||
| Cost of product revenue | 20,415,000 | 15,966,000 |
| Cost of service and other revenue | 6,135,000 | 5,891,000 |
| Total cost of revenue | 26,550,000 | 21,857,000 |
| Operating expenses: | ||
| Research and development | 54,032,000 | 49,047,000 |
| Selling, general and administrative | 93,499,000 | 88,596,000 |
| Goodwill impairment | 77,280,000 | — |
| Total operating expenses | 224,811,000 | 137,643,000 |
| Loss from operations | (215,245,000) | (131,698,000) |
| Other expenses | ||
| Interest income | 3,311,000 | 1,507,000 |
| Interest expense | (5,119,000) | (298,000) |
| Other income (expenses) | 3,449,000 | (223,000) |
| Loss on High Trail Agreement | (18,827,000) | — |
| Total other income (expense) | (17,186,000) | 986,000 |
| Loss before income taxes | (232,431,000) | (130,712,000) |
| Benefit (provision) for income taxes | (62,000) | (1,884,000) |
| Net loss | $(232,493,000) | $(132,596,000) |
| Net loss per share, basic and diluted | $(6.81) | $(4.58) |
| Weighted-average common shares outstanding, basic and diluted | 34,150,000 | 28,921,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.